Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases

• Published in: Breast cancer research and treatment Vol. 176; no. 2; pp. 321 - 328
• Main Authors: Sambade, Maria J., Prince, Grace, Deal, Allison M., Trembath, Dimitri, McKee, Megan, Garrett, Amy, Keith, Kevin, Ramirez, Juanita, Midkiff, Bentley, Blackwell, Kimberly, Sammons, Sarah, Leone, Jose Pablo, Brufsky, Adam, Morikawa, Aki, Brogi, Edi, Seidman, Andrew, Ewend, Matthew, Carey, Lisa A., Moschos, Stergios J., Hamilton, Ronald L., Vincent, Benjamin, Anders, Carey
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2019; Springer; Springer Nature B.V
• Subjects: Analysis; Biomarkers; Brain cancer; Breast cancer; Cancer research; Clinical Trial; ErbB-2 protein; Gliosis; Health aspects; Hemorrhage; Medical prognosis; Medicine; Medicine & Public Health; Melanoma; Metastases; Metastasis; Necrosis; Oncology; Prognosis; Immune infiltrate; Prognosis; Breast cancer brain metastases; Microenvironment
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-019-05211-1

Purpose Brain metastases (BM) are a complication of advanced breast cancer (BC). Histology of melanoma BM offers prognostic value; however, understanding the microenvironment of breast cancer brain metastases (BCBM) is less characterized. This study reports on four histological biomarkers, gliosis, immune infiltrate, hemorrhage, necrosis, and their prognostic significance in BCBM. Methods A biobank of 203 human tissues from patients who underwent craniotomy for BCBM was created across four academic institutions. Degree of gliosis, immune infiltrate, hemorrhage, and necrosis were identified and scored via representative H&E stain (0–3+). Overall survival (OS) was estimated using the Kaplan–Meier method. Cox proportional hazards regression evaluated prognostic value of the biomarkers in the context of standard clinical characteristics. Results BCBM subtype (available for n  = 158) was 36% Her2+, 26% hormone receptor (HR)+/Her2− 38% HR−/Her2− (triple negative, TN). Gliosis was observed in 82% (116/141) of BCBM, with immune infiltrate 44% (90/201), hemorrhage 82% (166/141), and necrosis 87% (176/201). Necrosis was significantly higher in TNBC ( p  < 0.01). Presence of gliosis, immune infiltrate, and hemorrhage correlated with improved OS ( p  = 0.03, p  = 0.03, p  = 0.1), while necrosis correlated with inferior OS ( p  = 0.01). Improved OS was associated with gliosis in TN ( p  = 0.02), and immune infiltrate ( p  = 0.001) and hemorrhage ( p  = 0.07) in HER2+. In a multivariable model for OS, incorporating these biomarkers with traditional clinical variables improved the model fit ( p  < 0.001). Conclusion Gliosis confers superior prognosis in TNBC BM; immune infiltrate and hemorrhage correlate with superior prognosis in HER2+ BCBM. Understanding the metastatic microenvironment of BCBM refines prognostic considerations and may unveil novel therapeutic strategies.